Windtree Therapeutics, Inc. · OTC:WINT

Windtree Therapeutics — Investor Presentation (November 2022)

42 slides from Windtree Therapeutics's investor presentation, Nov 14, 2022

  1. Slide 1: Windtree Therapeutics Company Overview

    Windtree Therapeutics a, Company Overview November 14, 2022 SV i) WINDTREE (NASDAQ: WINT)

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation includes forward-looking statements within the meaning of Section 27Aof the Securities Actof 1933, as amended, and Section 21E ofthe Securities Exchange Act of 1934, as amended. These statements, among other things, include statements about the ‘Company's

  3. Slide 3: Windtree Therapeutics and Istaroxime Highlights

    Windtree Therapeutics and Istaroxime Highlights vi (vj Biopharmaceutical company with advanced clinical focused on significant acute CV markets with high unmet needs and with supportive regulatory paths and designations (NASDAQ: WINT) Through three Phase 2 global studies, lead asset istaroxime has c

  4. Slide 4: Pipeline

    Pipeline Lead Products _| indication Phase Istaroxime Early Cardiogenic Shock Phase 2 Istaroxime Acute Heart Failure Phase 2b OralSERCAZa Chronic Heart Faliue, including prechnical Activators potential HEPEF Rostafuroxin jnetcol Assocaled Phase 2b KUABurtactant MUA surfactant DripDevce Tx FF RDS and

  5. Slide 5: Istaroxime: Early Cardiogenic Shock

    Istaroxime Early Cardiogenic Shock Potential indication in active clinical development

  6. Slide 6: Cardiogenic Shock

    Cardiogenic Shock A severe presentation of heart failure characterized by very low blood pressure and hypoperfusion accompanied by high filling pressures of the heart and decreased urine output. Itis a treatment emergency » Caused by severe impairment of cardiac function that results in diminished c

  7. Slide 7: Market Research: Early Cardiogenic Shock Treatment

    Market Research’ Early Cardiogenic Shock Treatment Istaroxime Potential Opportunity to Address Significant Unmet Need + No satisfactory pharmacological intervention to reverse the conditions ~ Available therapies have unwanted side effects such as risk for arrhythmias, decreasing blood pressure, ren

  8. Slide 8: Istaroxime: Novel First-in-Class Therapy

    Istaroxime — Novel ‘st-in-Class Therapy Novel intravenous agent designed to improve systolic contraction and diastolic relaxation of the heart Dual Mechanism of Action Inhibition of the s potassium pump and effects on Istaroxime the sodium-calcium exchanger results in increased contraction Impact on

  9. Slide 9: Rationale for Istaroxime in Cardiogenic Shock Came from AHF Phase 2 Trials

    Rationale for Istaroxime in Cardiogenic Shock Came from AHF Phase 2 Trials E/e’ (cardiacfilling pressure) Istaroxime 1.0 yg/kgimin vs. placebo Stroke Volume 1 - * p-value = 0.009 sR 3 WINDTREE Systolic Blood Pressure (SBP) Istaroxime 1.0 yg/kgimin vs. placebo =? pvaue=0011 2, prvalues 50.006 Improve

  10. Slide 10: Early Cardiogenic Shock Treatment: Opportunity for Accelerated Pathway

    Early Cardiogenic Shock Treatment Istaroxime Potential Opportunity for Accelerated Pathway Potential for a relatively fast and less expensive developmental and regulatory pathway FDA Regulatory Commentary with Break-Through Therapy Designation Potential 7 & Sponsors are potentially not required to s

  11. Slide 11: SEISMiC Early Cardiogenic Shock Study

    SEISMIC Early Cardiogenic Shock Study Clinical strategy: Start development with patients in early cardiogenic shock caused by severe heart failure =D 60 patients in early cardiogenic shock (SBP 75-90mmHg) with AHF Study drug was infused for 24 hours in a 1:1 randomization to placebo or istaroxime. T

  12. Slide 12: Difference in SBP Profile

    SN cz Difference in SBP Profile Systolic Blood Pressure AUC through 6 Hours - mITT Population mr) Bistaroxime e Bb @Placebo Bn a! Bio £9 zs 30 tig Es &s B3 3 com ee ° o os 1 1s 2 2 3 35 4 45 5 55 6 & Hours from Infusion Inititation WINDTREE 2

  13. Slide 13: Secondary Results

    \ Secondary Results Systolic BP Improvements Persisted over 24 Hours Systolic Blood Pressure mITT Population 20 40 ~*Istaroxime 3 ‘© Placebo 2 = & rs a é t t { p=0.025 for AUC 2 ° 0 2 2 Hours from Infusion initiation ae WINDTREE

  14. Slide 14: Cardiac Function Improvement

    Cardiac Function Improvement Echocardiography demonstrated improvements in key systolic and diastolic cardiac function measures including: * Cardiac index significantly increased » Stroke volume index substantially increased (4 mL/m?) approaching statistical significance * Other echocardiographic me

  15. Slide 15: Treatment was Associated with a Favorable Renal Profile

    Treatment was Associated with a Favorable Renal Profile Renal function was not decreased in istaroxime treated patients Estimated Glomerular Filtration Rate miTT Population ‘change from Baseline in eGR (mliminit.73m2) o 2 24 6 e 60 7 e % Hours from Infusion initiation WINDTREE TREE ost choanas mesns

  16. Slide 16: Comparison of Doses

    \ Comparison of Doses 1.0 yg/kg/min Produced a Favorable Effect on SBP 1.0 g/kg/min dosing was associated with: * Early, rapid SBP increase and improvement in more echocardiographic assessments of cardiac function + More favorable adverse event, serious adverse event and clinical event profile 21.0

  17. Slide 17: SEISMiC Results Summary

    SEISMiC Results Summary SEISMIC was a positive study in early cardiogenic shock patients v Systolic blood pressure significantly increased within the first 6 hours of initiating the infusion (p=0.017) and the increase was maintained throughout the 24-hour infusion (p=0.025) » SBP increases were rapi

  18. Slide 18: Cardiogenic Shock Opportunity

    Cardiogenic Shock Opportunity INTENDED TARGET THERAPEUTIC PROFILE “For patientsin cardiogenic shock due to heart failure, Istaroxime will be a unique, first-in-class dual action agent and the only treatment for cardiogenicshock that rapidly and significantly improves blood pressure and cardiac outpu

  19. Slide 19: Cardiogenic Shock Development Strategy

    Cardiogenic Shock Development Strategy SEISMIC Extension Study = Extended and titrated dosing for optimization SEISMIC * Additional characterization Phase 3* Of SERCAZA effect * Execute EOP2 meeting Study with these 3 studies augmented by AHF * Proof of Concept eS safety data base, etc. = SCAI Stage

  20. Slide 20: Plan for Dose Optimization: Extension Study

    Plan for Dose Optimization — Extension Study Following the positive results in the early cardiogenic shock study, an extension study is planned to support ongoing development in early cardiogenic shock and acute heart failure Study objectives: v Advance the characterization of the physiology associa

  21. Slide 21: Istaroxime: Acute Heart Failure

    Istaroxime Dual Mechanism SERCA2a Activator Acute Heart

  22. Slide 22: Heart Failure: Large, Growing Market But Underserved

    Heart Failure — Large, Growing Market But Underserved The prevalence and mortality of heart failure is high and increasing Patients TMs, 25M + wortawide Annual Admissions #1 cause of U.S. hospitalization ~1.3M us. in patients os > 65 years old SM ev >$18B c& In-patient mortality annual U.S. hospital

  23. Slide 23: Acute Heart Failure: Significant Unmet Clinical Need

    Acute Heart Failure — Significant Unmet Clinical Need tient Management Goals Current Treatment Options * Clinical objectives for AHF » Current approaches to acutely improve cardiac patient management include: function are associated with unwanted effects: Relieve pulmonary Heart rhythm disturbances

  24. Slide 24: Istaroxime AHF Phase 2a & 2b Studies

    Istaroxime AHF Phase 2a & 2b Studies Phase 2a Phase 2b 7 & WInDTREE 9) + Primary: PCWP significantly improved 7 + Stroke Vol & SBP — significantincrease n=120 Dosing Ghour «Heart Rate (HR) - lowered ADHF Patients 0.5, 1, 1.5 ygkgimin Infusion n=120 Dosing= 24 hour ADHF Patients 0.5, 1.0 vokaimin Inf

  25. Slide 25: Primary Endpoint Achieved

    Primary Endpoint Achieved Significant Changes in E/e' Ratio’ and Stroke Volume sR Cy WINDTREE Istaroxime 0.5 yg/kg/min vs. placebo Ele’ 0 infusion period er Bassin Ohaus 2ehours «Bours = Pleet0-Ceton— eetstexoxne 0 Sugg qe ipa Stroke E20 Volume “ Infusion period Sonoma te’ echocarlograptic assessmen

  26. Slide 26: Systolic Blood Pressure Increased During Treatment and Renal Function Tended to Improve

    Systolic Blood Pressure Increased During Treatment and Renal Function Tended to Improve Istaroxime 0.5 yg/kg/min vs. placebo Istaroxime 1.0 ug/kg/min vs. placebo ® 2 oy 3° Systolic 3° “paver 90%, g° Blood == * ba a: Pressure 3 eek - as (ser) Zo g. Bs 8 a infusion peed ison per ‘esse canen roi O° BON

  27. Slide 27: Heart Rate Decreased and No Increases in Cardiac Troponins

    Heart Rate Decreased and No Increases in Cardiac Troponins Istaroxime 0.5 ug/kg/min vs. placebo ‘ Infusion period *pvaive= 0014 5 ann cTnT-0to 24 hours, Cardiac TaT (Myocardial Damage) BY eset espana = 5 Pe WINDTREE Istaroxime 1.0 yg/kg/min vs. placebo pvaue=0.011 rvalues <0 065 @

  28. Slide 28: Favorable Profile Observed with 24-hour Holter Monitoring

    Favorable Profile Observed with 24-hour Holter Monitoring Clinically Significant Arrhythmias 120% 2508 705% 0% 705% ‘ 200% 200% 200% 00% 200% 20% 150% 129% com 100% 100% 100% 40% 2% 2% 2% ne 50% 20% ox ation ay ato) a2 e2sne ay (ron) bay? sPiceto- Comat lataorine OS ypkgimn Placebo -caben2 iszouine

  29. Slide 29: Istaroxime: Acute Heart Failure Next Study

    NES Istaroxime — Acute Heart Failure Objective: Optimize therapy and employ study enrichment strategies to create strong Phase 3 and partnership position Execute an additional study designed to complete Phase 2 and inform Phase 3 300 patients, 60 centers globally* Enrich therapeutic impact by levera

  30. Slide 30: Next Generation, Oral SERCA2a Activators Acute and Chronic Heart Failure Platform

    Next Generation, Oral SERCA2a Activators Acute and Chronic Heart Failure Platform The Company also has pre-clinical programs on product candidates including: Selective SERCA2a Dual Mechanism, (SERCA2a & Na+/K+) Activators Compounds. + Oral & i.v. therapies for chronic “Next generation istaroxime” as

  31. Slide 31: Summary

    Summary v4) * Istaroxime has produced positive, differentiating data in three Phase 2 studies for two - separate and complementary indications. These markets have significant unmet needs, and no known other late-stage programs in development to address the acute decompensated patient ~ The data is c

  32. Slide 32: Funding Development

    Funding Development- Actively Engaged to Address Resources and Create Opportunity Windtree is actively engaged and assessing various options to fund development and operations including: Strategic Business Development — Capital Transaction Licensing Markets + Mergers & Acquisitions * Global or regio

  33. Slide 33: Financial Summary & Capitalization

    Financial Summary & Capitalization Cash & Equivalents of ~$8.4 million as of September 30, 2022 es Equivalents jsetiuiles es of November 14, 2022 Common Stock 38,610,119 Options (WAEP $7.64) 3,883,169 Restricted Stock Units 558,100 Warrants (WAEP $6.64) 16,546,336 Fully Diluted Equivalents 59,597,72

  34. Slide 34: Strategy for Value Generation

    Strategy for Value Generation Communicate Our . Milestones Transactions Y ‘Secure focused BD transactions for deal revenue and non-dilutive financial support of clinical development Progress heart failure platform to an attractive and valuable position for global partnership (while retaining US co-p

  35. Slide 35: Slide 35

  36. Slide 36: Appendix

    Appendix

  37. Slide 37: Istaroxime Unique Opportunity With Attractive Risk / Return Profile

    Istaroxime Unique Opportunity With Attractive Risk / Return Profile @ Highly consistent results across 3 © Attractive profile as the only acute heart failure or shock drug that has controlled Phase 2 studies (and been shown to significantly improve cardiac function of a failing heart, 300 patients d

  38. Slide 38: Istaroxime Phase 2a (HORIZON-HF) Study

    Istaroxime Phase 2a (HORIZON-HF) Study + Multicenter, double blind, placebo-controlled, doses 6-hour infusion of istaroxime 0.5, 1.0, 1.5 ug/kg/min, conducted in the EU + Hospitalized with AHF, with criteria including: LVEF s 35% SBP 90-150 mmHg 120 (30/group) + Significant improvement in PCWP, SBP,

  39. Slide 39: Istaroxime AHF Phase 2b Adverse Events

    Istaroxime AHF Phase 2b Adverse Events Pooled placebo _—Istaroxime 0.5 mg/Kgimin_Istaroxime 1.0 mg/Kgimin (n=39) (n=41) (n=40) All adverse events, 23 (69.0%) 31 (75.6%) 33 (62.5%) ‘Adverse events leading to discontinuation 12.6%) : 4 (10.0%) Serious adverse events, 26.1%) 2(49%) 6 (150%) Cardiac dea

  40. Slide 40: SEISMiC: Serious Adverse Events and Adverse Drug Reactions

    SEISMIC: Serious Adverse Events and Adverse Drug Reactions Istaroxime Placebo Event (N=29) 1) All adverseevents 27 (93%) 25 (81%) Serious adverse events 6(21%) 6 (19%) Cardiac arrest 1(3%) ° Cardiac failure 2(7%) 2 (6%) Cardiac failure acute 0 1(3%) Cardiac ventricular thrombosis ) 1 (3%) Cardiac ar

  41. Slide 41: SEISMiC: Safety and Efficacy Appeared More Favorable with 1.0 vs 1.5 µg/kg/min and Placebo

    SEISMIC: Safety and Efficacy Appeared More Favorable with the 1.0 vs 1.5 g/kg/min and Placebo 1.0 pg/kg/min dosing was associated with: + Early SBP increase and improvement in more echocardiographic parameters of cardiac function More favorable adverse event, serious adverse event and clinical event

  42. Slide 42: Acute Heart Failure: Significant Healthcare Issue with Significant Unmet Clinical Need

    Acute Heart Failure Significant Healthcare Issue with Significant Unmet Clinical Need * Patients with low blood pressure (SBP) and peripheral hypoperfusion are high risk, challenging patients. These patients are also generally resistant to diuretic therapy and often discharged in a sub-optimal state

Windtree Therapeutics — Investor Presentation (November 2022) on 6ix